Dexmedetomidine Supported Office Based Genioplasty: A Pilot Study

Area of Science:

• Dental Surgery
• Pharmacology
• Anesthesiology

Background:

• The search for novel sedative agents for dental procedures is ongoing.
• Dexmedetomidine, a selective α2 adrenergic receptor agonist, is approved for short-term sedation in ICU settings.
• Off-label use of dexmedetomidine has shown encouraging results in various procedural sedation contexts.

Purpose of the Study:

• To evaluate the clinical efficacy of dexmedetomidine for procedural sedation.
• To assess dexmedetomidine's safety and effectiveness in patients undergoing office-based sliding genioplasty.

Main Methods:

• A pilot study was conducted on adult patients undergoing office-based sliding genioplasty.
• Patients received dexmedetomidine with a loading dose (0.5 mcg/kg over 10 min) followed by maintenance infusion (0.1 mcg/kg/h).
• Clinical parameters including SpO2, MAP, HR, respiratory rate, Ramsay sedation score, and pain scale were monitored pre-, intra-, and post-operatively.

Main Results:

• Dexmedetomidine facilitated procedural sedation for sliding genioplasty.
• Hemodynamic and respiratory parameters remained stable during the procedure.
• Patients achieved adequate sedation levels with a manageable recovery period.

Conclusions:

• Dexmedetomidine is a potentially effective and safe sedative agent for office-based surgical procedures like sliding genioplasty.
• Further research is warranted to confirm these findings in larger patient cohorts.